Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV001289171 | SCV001476819 | pathogenic | not provided | 2024-09-30 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population is consistent with pathogenicity. (http://gnomad.broadinstitute.org) This variant is not expected to cause loss of protein expression through nonsense-mediated decay. However, it disrupts a critical region of the protein, and therefore, is expected to severely disrupt its function. This variant has been identified in at least one individual tested at Athena Diagnostics with clinical features associated with this gene. |
Natera, |
RCV001830105 | SCV002086275 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2021-02-02 | no assertion criteria provided | clinical testing |